Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer
-
Published:2024-06
Issue:
Volume:50
Page:101102
-
ISSN:0147-0272
-
Container-title:Current Problems in Cancer
-
language:en
-
Short-container-title:Current Problems in Cancer
Author:
Kutlu YasinORCID,
Cekin Ruhper,
Aydin Sabin Goktas,
Shbair Abdallah T M,
Bilici Ahmet,
Arici Serdar,
Oven Bala Basak,
Acikgoz Ozgur,
Ozcan Erkan,
Olmez Omer Fatih,
Cakir Asli,
Seker Mesut
Reference22 articles.
1. Cancer statistics, 2021;Siegel;CA Cancer J Clin,2021
2. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001
3. Evolving standards of care and new challenges in the management of HER2-positive breast cancer;Choong;CA Cancer J Clin,2020
4. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL–CALGB 150007/150012, ACRIN 6657;Esserman;J Clin Oncol,2012
5. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial;Gianni;Lancet Oncol,2016
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献